These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Molecular characterization of laforin, a dual-specificity protein phosphatase implicated in Lafora disease. Girard JM; Lê KH; Lederer F Biochimie; 2006 Dec; 88(12):1961-71. PubMed ID: 17010495 [TBL] [Abstract][Full Text] [Related]
45. Laforin is required for the functional activation of malin in endoplasmic reticulum stress resistance in neuronal cells. Zeng L; Wang Y; Baba O; Zheng P; Liu Y; Liu Y FEBS J; 2012 Jul; 279(14):2467-78. PubMed ID: 22578008 [TBL] [Abstract][Full Text] [Related]
46. Expression of the functional carbohydrate-binding module (CBM) of human laforin. Moreira S; Castanheira P; Casal M; Faro C; Gama M Protein Expr Purif; 2010 Dec; 74(2):169-74. PubMed ID: 20600946 [TBL] [Abstract][Full Text] [Related]
47. Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG). Worby CA; Gentry MS; Dixon JE J Biol Chem; 2008 Feb; 283(7):4069-76. PubMed ID: 18070875 [TBL] [Abstract][Full Text] [Related]
48. Interdependence of laforin and malin proteins for their stability and functions could underlie the molecular basis of locus heterogeneity in Lafora disease. Mittal S; Upadhyay M; Singh PK; Parihar R; Ganesh S J Biosci; 2015 Dec; 40(5):863-71. PubMed ID: 26648032 [TBL] [Abstract][Full Text] [Related]
49. Lafora disease in the Indian population: EPM2A and NHLRC1 gene mutations and their impact on subcellular localization of laforin and malin. Singh S; Satishchandra P; Shankar SK; Ganesh S Hum Mutat; 2008 Jun; 29(6):E1-12. PubMed ID: 18311786 [TBL] [Abstract][Full Text] [Related]
50. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. Ganesh S; Agarwala KL; Ueda K; Akagi T; Shoda K; Usui T; Hashikawa T; Osada H; Delgado-Escueta AV; Yamakawa K Hum Mol Genet; 2000 Sep; 9(15):2251-61. PubMed ID: 11001928 [TBL] [Abstract][Full Text] [Related]
51. A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen. Wang J; Stuckey JA; Wishart MJ; Dixon JE J Biol Chem; 2002 Jan; 277(4):2377-80. PubMed ID: 11739371 [TBL] [Abstract][Full Text] [Related]
53. Oxidative stress, a new hallmark in the pathophysiology of Lafora progressive myoclonus epilepsy. Romá-Mateo C; Aguado C; García-Giménez JL; Knecht E; Sanz P; Pallardó FV Free Radic Biol Med; 2015 Nov; 88(Pt A):30-41. PubMed ID: 25680286 [TBL] [Abstract][Full Text] [Related]
54. Laforin prevents stress-induced polyglucosan body formation and Lafora disease progression in neurons. Wang Y; Ma K; Wang P; Baba O; Zhang H; Parent JM; Zheng P; Liu Y; Minassian BA; Liu Y Mol Neurobiol; 2013 Aug; 48(1):49-61. PubMed ID: 23546741 [TBL] [Abstract][Full Text] [Related]
55. Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Gentry MS; Worby CA; Dixon JE Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8501-6. PubMed ID: 15930137 [TBL] [Abstract][Full Text] [Related]
58. A novel EPM2A mutation yields a slow progression form of Lafora disease. Garcia-Gimeno MA; Rodilla-Ramirez PN; Viana R; Salas-Puig X; Brewer MK; Gentry MS; Sanz P Epilepsy Res; 2018 Sep; 145():169-177. PubMed ID: 30041081 [TBL] [Abstract][Full Text] [Related]
59. Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease. Puri R; Suzuki T; Yamakawa K; Ganesh S J Biol Chem; 2009 Aug; 284(34):22657-63. PubMed ID: 19542233 [TBL] [Abstract][Full Text] [Related]
60. The laforin-malin complex negatively regulates glycogen synthesis by modulating cellular glucose uptake via glucose transporters. Singh PK; Singh S; Ganesh S Mol Cell Biol; 2012 Feb; 32(3):652-63. PubMed ID: 22124153 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]